Isradipine

• CAT Number: A000767
• CAS Number: 75695-93-1
• Molecular Formula: C19H21N3O5
• Molecular Weight: 371.4
• Purity: ≥95%
• Synonyms: 75695-93-1; DynaCirc; Isradipin; Lomir; Isrodipine
• Target: Calcium Channel
• Solubility: >12.6mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
• InChIKey: HMJIYCCIJYRONP-UHFFFAOYSA-N
• SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC

Isradipine is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. More recent research in animal models suggests that isradipine may have potential uses for treating Parkinson/’s disease.

Reference

1: Ortner NJ, Bock G, Dougalis A, Kharitonova M, Duda J, Hess S, Tuluc P,
Pomberger T, Stefanova N, Pitterl F, Ciossek T, Oberacher H, Draheim HJ,
Kloppenburg P, Liss B, Striessnig J. Lower Affinity of Isradipine for L-Type
Ca(2+) Channels during Substantia Nigra Dopamine Neuron-Like Activity:
Implications for Neuroprotection in Parkinson/’s Disease. J Neurosci. 2017 Jul
12;37(28):6761-6777. doi: 10.1523/JNEUROSCI.2946-16.2017. Epub 2017 Jun 7. PubMed
PMID: 28592699.

2: Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J,
Rockhill R, Shoulson I, Venuto C, Young D, Simuni T; Parkinson Study Group
STEADY‐PD III Investigators. A novel design of a Phase III trial of isradipine in
early Parkinson disease (STEADY-PD III). Ann Clin Transl Neurol. 2017 May
9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun. PubMed PMID:
28589163; PubMed Central PMCID: PMC5454402.

3: Wang QM, Xu YY, Liu S, Ma ZG. Isradipine attenuates MPTP-induced dopamine
neuron degeneration by inhibiting up-regulation of L-type calcium channels and
iron accumulation in the substantia nigra of mice. Oncotarget. 2017 Jul
18;8(29):47284-47295. doi: 10.18632/oncotarget.17618. PubMed PMID: 28521299;
PubMed Central PMCID: PMC5564564.

4: Thirupathi G, Swetha E, Narendar D. Role of Isradipine Loaded Solid Lipid
Nanoparticles on the Pharmacodynamic Effect in Rats. Drug Res (Stuttg). 2017
Mar;67(3):163-169. doi: 10.1055/s-0042-119947. Epub 2016 Dec 19. PubMed PMID:
27992936.

5: Kumar V, Kharb R, Chaudhary H. Optimization & design of isradipine loaded
solid lipid nanobioparticles using rutin by Taguchi methodology. Int J Biol
Macromol. 2016 Nov;92:338-346. doi: 10.1016/j.ijbiomac.2016.07.020. Epub 2016 Jul
5. PubMed PMID: 27392772.

6: Qadri GR, Ahad A, Aqil M, Imam SS, Ali A. Invasomes of isradipine for enhanced
transdermal delivery against hypertension: formulation, characterization, and in
vivo pharmacodynamic study. Artif Cells Nanomed Biotechnol. 2017
Feb;45(1):139-145. Epub 2016 Feb 1. PubMed PMID: 26829018.

7: Rotstein BH, Liang SH, Belov VV, Livni E, Levine DB, Bonab AA, Papisov MI,
Perlis RH, Vasdev N. Practical Radiosynthesis and Preclinical Neuroimaging of
[11C]isradipine, a Calcium Channel Antagonist. Molecules. 2015 May
26;20(6):9550-9. doi: 10.3390/molecules20069550. PubMed PMID: 26016546; PubMed
Central PMCID: PMC4870226.

8: Tran TT, Tran PH, Nguyen MN, Tran KT, Pham MN, Tran PC, Vo TV. Amorphous
isradipine nanosuspension by the sonoprecipitation method. Int J Pharm. 2014 Oct
20;474(1-2):146-50. doi: 10.1016/j.ijpharm.2014.08.017. Epub 2014 Aug 17. PubMed
PMID: 25138256.

9: Ramasahayam B, Eedara BB, Kandadi P, Jukanti R, Bandari S. Development of
isradipine loaded self-nano emulsifying powders for improved oral delivery: in
vitro and in vivo evaluation. Drug Dev Ind Pharm. 2015 May;41(5):753-63. doi:
10.3109/03639045.2014.900081. Epub 2014 Mar 18. PubMed PMID: 24641324.

10: Ostacher MJ, Iosifescu DV, Hay A, Blumenthal SR, Sklar P, Perlis RH. Pilot
investigation of isradipine in the treatment of bipolar depression motivated by
genome-wide association. Bipolar Disord. 2014 Mar;16(2):199-203. doi:
10.1111/bdi.12143. Epub 2013 Dec 27. PubMed PMID: 24372835.